CTFA/CHPA Urge Expanded Oral Health Care Indications
This article was originally published in The Tan Sheet
Executive Summary
FDA should broaden labeling guidance for the indications of OTC antigingivitis/antiplaque drug products under the "uses" heading to allow multiple descriptions of drug effects, the Joint Oral Care Task Group of the Consumer Healthcare Products Association and the Cosmetic, Toiletry & Fragrance Association recommends
You may also be interested in...
CTFA/CHPA Urge More Flexibility in Gingivitis Draft Guidance
FDA's draft guidance for antigingivitis drug development and evaluation should encourage the creation of new indices that provide "meaningful and clinically relevant measures" of gingivitis, according to industry trade groups
CTFA/CHPA Urge More Flexibility in Gingivitis Draft Guidance
FDA's draft guidance for antigingivitis drug development and evaluation should encourage the creation of new indices that provide "meaningful and clinically relevant measures" of gingivitis, according to industry trade groups
CTFA/CHPA Urge More Flexibility in Gingivitis Draft Guidance
FDA's draft guidance for antigingivitis drug development and evaluation should encourage the creation of new indices that provide "meaningful and clinically relevant measures" of gingivitis, according to industry trade groups